Virtual Library

Start Your Search

Beatriz Eugenia Jimenez Munarriz



Author of

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-29 - Mutational Landscape in Lung Cancer Patients by Targeted Next-Generation Sequencing and Differences by Gender in Spanish Population (Now Available) (ID 2700)

      08:00 - 18:00  |  Presenting Author(s): Beatriz Eugenia Jimenez Munarriz

      • Abstract
      • Slides

      Background

      Personalized treatment with matched therapies according to genomic alterations improve treatment outcome in advanced NSCLC and some genomic alterations are linked to sex. Next Generation Sequencing (NGS) is reliable tool for genomic profiling. We aim to search clinical and pathological differences by sex in NSCLC patients with a comprehensive genomic profile by NGS.

      Method

      We retrospective assess clinical-pathological and molecular characteristics of 73 stage I-IV lung cancer patients and NGS at baseline. NGS was performed in 67% by Oncomine TM, 30% by OCA v3 and 2% by Foundation One.

      Result

      The cohort included: 49% of females (F), the mean age was 63 years (40-85), 90% stage IV, 91% adenocarcinoma, followed by squamous cell carcinoma (9.5%) and small cell (2%). Former smoker were reported in 74% and 80% of male (M) and females, respectively. Primary tumor lung biopsy was the main source of sample for NGS in 90% of cases. The majority of somatic genomic alterations were mutations (64% M vs. 78% F), followed by CNV (19% M vs. 11% F) and rearrangements (17% M vs. 11% F). In both genders KRAS mutation (mut) was the most common (M vs. F) (27% vs. 28%), and wild-type tumors was reported in 20% and 9%, respectively. Regarding actionable drivers, there was a higher incidence of EGFR mut (18% vs. 9%), ALK rearrangements (6% vs. 4%) and HER 2 mut (6% vs 4%) in F vs M, respectively. As contrary BRAF mut (4% vs. 3%), and RET rearrangements (4% vs. 0%) were more frequent in M. Baseline brain metastases in patients with EGFR and BRAF mut was similar regardless of sex (50% and 0%), whereas in ALK and HER2 were more frequent in F (50% F vs. 0% M). Twenty-nine percent of patients received personalized treatment according to these results.

      Conclusion

      NGS can identify a significant proportion of therapeutically relevant driver alterations in LC leading personalized treatment. Some clinical features were found by gender in our population probably related to genomic differences linked to sex.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.